Biomolecules · 8 authors, 5 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
This narrative review synthesizes existing knowledge on SARS-CoV-2 virology, the role of the ACE2 receptor in viral entry, and the current landscape of repurposed and novel therapeutics for COVID-19. It concludes that effective antivirals and ways to control pathogenic inflammation are urgently needed.
This narrative review synthesizes publicly available information on the classification of coronaviruses, the clinical consequences of SARS-CoV-2 activating the angiotensin-converting enzyme 2 (ACE2) receptor, and the chemical nature of proposed therapeutics. It discusses the repurposing of antiviral drugs, such as nucleoside analogs, and summarizes the development of new treatments. The review highlights that hyperinflammation and coagulation disturbances contribute to disease severity and death. It notes that many clinical trials have been conducted and that the FDA has authorized various drugs, though some have been revoked due to toxicity or lack of mortality reduction. The review aims to guide future therapeutic design by summarizing past successes and failures.
